Dominic Rodrigues - 16 Sep 2022 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
Director
Signature
/s/ Dominic Rodrigues
Issuer symbol
PVCT
Transactions as of
16 Sep 2022
Net transactions value
+$3,267,334
Form type
4
Filing time
20 Sep 2022, 17:26:19 UTC
Next filing
23 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT Series D Convertible Preferred Stock Purchase $3,267,334 +11,416,262 $0.2862 11,416,262 16 Sep 2022 Common Stock 11,416,262 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Convertible Preferred Stock") is convertible into one share of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2 The Series D Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D Convertible Preferred Stock.